Docetaxel versus androgen receptor pathway inhibitors as first-line therapy for metastatic castration-resistant prostate cancer after doublet therapy: a multicenter retrospective study from Saudi Arabia
In patients progressing to mCRPC after doublet therapy in the CS setting, docetaxel demonstrated a trend toward longer PFS and OS compared to ARPI, with a significant survival advantage in those with visceral metastases. These findings highlight the need for prospective randomized trials and biomarker-driven treatment strategies to optimize therapy sequencing in this evolving treatment landscape.
Authors
- Tarek Ziad Arabi (ORCID: https://orcid.org/0000-0002-6292-7683)
- Noura Alzannan
- Tusneem Elhassan (ORCID: https://orcid.org/0000-0002-1625-1168)
- Fahad Almugbel
- Waleed Fallatah
- Muhammad Shahzad Rauf
- Shouki Bazarbashi
- Albatool Busbaih
- Mohamed Aseafan
- Faisal Azam
- Mohammed Mahroos
- Ahmed S. Abdelmotal
- Rajaa Aldandan
- Maram Aljishi
- Mubarak Almansour
Institutions
- Ain Shams University (EG)
- Alfaisal University (SA)
- King Saud bin Abdulaziz University for Health Sciences (SA)
- King Fahad Specialist Hospital (SA)
- Security Forces Hospital (SA)
Publication Details
- Journal
- BMC Urology
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1186/s12894-025-02019-8
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00